This will be a prospective, two group, time series, quasi- experimental study of the natural history of human immunodeficiency virus (HIV) infection in infants of drug addicted mothers.
The specific aims of this study are to: 1) measure the immunologic aberrations that result from HIV infection, maternal drug addiction and the confluence of these variables, 2) determine the vertical transmission rate and timing (transplacental versus natal) of infection, 3) identify maternal characteristics that are associated with the highest frequency of HIV transmission and 4) identify indicators that re prognostic of progressive disease at a time when children are clinically well. This information is needed to define the preclinical immunologic patterns that result from HIV infection and differentiate those that result from other factors. Information on the rate and timing of HIV transmission will guide maternal counselling regarding family planning, as well as direct potential intervention strategies, that could ultimately result in decreased transmission to children. Accurate identification of HIV infection depends on new strategies in the first 12 months of life when serologic diagnosis is confounded by passive maternal antibody. Identifying transmission risks and early indicators of prognosis will lead to better preventive and therapeutic strategies. Over the 5 year study we will enroll 200 drug addicted mothers and their infants and 30 HIV infected mothers (and their infants) who have sexual contact as their only risk. After informed consent is obtained subjects will be interviewed about drug use and other risk factors and blood samples will be obtained (15 ml in mothers and 4 ml in infants and children). Data will be coded without direct identifiers. Blood will be tested for HIV by culture using reverse transcriptase and antigen detection; for HIV antigen using antigen capture methods, HIV antibody studies using ELISA, Western Blot, anti p121 and p24 IgG subclass assay using a dot- blot ELISA, HIV specific IgM using immunofluorescence, T lymphocyte typing, and specific cell mediated and humoral responses to antigens and mitogens (CMI). Data will be entered in our NCR PC6 computer and analyzed using log linear model analysis or logistic regression. Study parameters will be analyzed with reference to clinical course of patients to determine prognosis. Confidentiality of subjects will be preserved; counselling about results and meaning of HIV tests will be provided.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Research Project (R01)
Project #
5R01DA004791-03
Application #
3210517
Study Section
Special Emphasis Panel (SRCD (14))
Project Start
1988-04-01
Project End
1993-03-31
Budget Start
1990-04-01
Budget End
1991-03-31
Support Year
3
Fiscal Year
1990
Total Cost
Indirect Cost
Name
New York University
Department
Type
Schools of Medicine
DUNS #
004514360
City
New York
State
NY
Country
United States
Zip Code
10012
Chandwani, S; Kaul, A; Bebenroth, D et al. (1996) Cytomegalovirus infection in human immunodeficiency virus type 1-infected children. Pediatr Infect Dis J 15:310-4
Bourinbaiar, A S; Krasinski, K; Borkowsky, W et al. (1995) Protective effect of interferon-alpha against cell-mediated human immunodeficiency virus transmission resulting from coculture of infected lymphocytes with fetal trophoblasts. J Interferon Cytokine Res 15:503-8
Arlievsky, N Z; Pollack, H; Rigaud, M et al. (1995) Shortened survival in infants vertically infected with human immunodeficiency virus with elevated p24 antigenemia. J Pediatr 127:538-43
Rigaud, M; Pollack, H; Leibovitz, E et al. (1994) Efficacy of primary chemoprophylaxis against Pneumocystis carinii pneumonia during the first year of life in infants infected with human immunodeficiency virus type 1. J Pediatr 125:476-80
Bourinbaiar, A S; Lee-Huang, S; Krasinski, K et al. (1994) Anti-HIV effect of immunomodulating agent, levamisole, in vitro. Biomed Pharmacother 48:327-30
Bourinbaiar, A S; Lee-Huang, S; Krasinski, K et al. (1994) Inhibitory effect of the oral immune response modifier, bestatin, on cell-mediated and cell-free HIV infection in vitro. Biomed Pharmacother 48:55-61
Bourinbaiar, A S; Krasinski, K; Borkowsky, W (1994) Anti-HIV effect of gramicidin in vitro: potential for spermicide use. Life Sci 54:PL5-9
Chandwani, S; Moore, T; Kaul, A et al. (1993) Early diagnosis of human immunodeficiency virus type 1-infected infants by plasma p24 antigen assay after immune complex dissociation. Pediatr Infect Dis J 12:96-7
Pollack, H; Zhan, M X; Ilmet-Moore, T et al. (1993) Ontogeny of anti-human immunodeficiency virus (HIV) antibody production in HIV-1-infected infants. Proc Natl Acad Sci U S A 90:2340-4
Pollack, H; Zhan, M X; Ilmet-Moore, T et al. (1993) A novel detection assay for the early diagnosis of HIV-1 infected infants. J Acquir Immune Defic Syndr 6:582-6

Showing the most recent 10 out of 17 publications